GFAP (Glial Fibrillary Acidic Protein) is an intermediate filament protein expressed primarily in astrocytes that serves as a sensitive blood and CSF biomarker for astrocyte activation (astrogliosis) in neurodegenerative diseases. GFAP is increasingly recognized as a valuable diagnostic marker for distinguishing between different neurodegenerative disorders.
GFAP is a type III intermediate filament protein that:
- Provides structural support to astrocytes and neural progenitor cells
- Maintains astrocyte morphology and polarity
- Regulates glutamate uptake and metabolism
- Modulates blood-brain barrier function
When astrocytes become activated in response to neurodegeneration, GFAP expression increases significantly. This makes GFAP a marker of astrogliosis and a surrogate for neuroinflammatory processes in the brain.
GFAP is the most widely used marker for reactive astrocytosis:
| State |
GFAP Expression |
Interpretation |
| Homeostatic |
Low basal levels |
Normal astrocyte function |
| Reactive Astrogliosis |
2-10x increase |
Neuroinflammation or neurodegeneration |
- Blood GFAP: Elevated in AD patients, correlates with Aβ pathology
- Diagnostic accuracy: AUC 0.78-0.85 for AD vs controls
- Prognostic value: Higher levels predict faster cognitive decline
- Detects early:Elevated CSF GFAP detectable years before clinical symptoms
- Blood GFAP: Moderately elevated in PD
- Differentiates synucleinopathies: Higher in MSA than PD (AUC 0.82)
- Progression marker: Levels correlate with disease severity (UPDRS)
- CSF GFAP: Elevated in CBS reflecting astrocyte pathology
- Pattern: Similar to PSP with moderate elevations (40-60 ng/mL in CSF)
- Differential diagnosis: Helps distinguish from AD and DLB
- Astrocytic plaques: CBD-specific pathology correlates with GFAP
- CSF GFAP: Intermediate elevation between PD and MSA
- PSP-RS correlation: Higher levels correlate with greater clinical severity
- Diagnostic utility: Differentiates PSP from PD (AUC 0.82)
- Midbrain atrophy: GFAP correlates with imaging measures
| Condition |
CSF GFAP (ng/mL) |
Blood GFAP (pg/mL) |
Key Pattern |
| Healthy Controls |
10-30 |
80-120 |
Baseline |
| Alzheimer's Disease |
40-60 |
200-300 |
High, Aβ-linked |
| Parkinson's Disease |
25-40 |
120-180 |
Moderate |
| Multiple System Atrophy |
50-80 |
200-350 |
Highest α-syn |
| CBS |
40-60 |
180-280 |
Tau-linked |
| PSP |
35-55 |
160-260 |
Intermediate |
- PSP Rating Scale (PSP-RS): Positive correlation with CSF GFAP
- UPDRS (PD): Levels associate with motor severity
- MMSE/ADAS-Cog (AD): Inverse correlation with cognitive scores
- ALSFRS-R (ALS): Negative correlation with functional ratings
- Brain atrophy: GFAP correlates with ventricular enlargement
- Midbrain atrophy (PSP): Higher GFAP associated with greater midbrain volume loss
- Cortical thinning (CBS): Correlates with frontal/parietal atrophy rates
- Simoa (Single Molecule Array): Ultra-sensitive, detects pg/mL levels
- ELISA: Standard clinical assays
- Advantages: Minimally invasive, suitable for longitudinal monitoring
- CSF correlation: Blood and CSF levels show good correlation (r=0.72-0.85)
- Gold standard for neurological assessment
- ELISA quantification (typical range: 10-50 ng/mL in healthy controls)
- Elevated 2-5x in neurodegenerative diseases
GFAP performs best in combination with other biomarkers:
| Combination |
AUC (AD vs Controls) |
Use Case |
| GFAP + p-tau181 |
0.88-0.92 |
Early AD detection |
| GFAP + NfL |
0.85-0.90 |
Disease progression |
| GFAP + Aβ42/40 |
0.90-0.95 |
Preclinical screening |
| GFAP + p-tau + NfL |
0.93-0.97 |
Comprehensive panel |
- Pelkmans et al. (2022) GFAP as a biomarker in Alzheimer's disease
- Elahi et al. (2022) Blood GFAP reflects astrocyte activation in AD
- Jang et al. (2023) CSF GFAP differentiates Parkinson's disease from atypical parkinsonism
- Pereira et al. (2023) Plasma GFAP detects tauopathy
| Population |
Mean |
Range (80% sensitivity) |
| Healthy Controls |
100 |
40-200 |
| MCI |
175 |
80-350 |
| Alzheimer's Disease |
250 |
100-500 |
| Parkinson's Disease |
150 |
60-300 |
| CBS/PSP |
200 |
100-400 |
- AD vs Controls: >150 pg/mL (blood)
- MCI progression: >180 pg/mL predicts progression to AD
- CBS/PSP vs PD: >180 pg/mL suggests atypical parkinsonism
- Specificity: GFAP elevation is not disease-specific; elevated in multiple conditions
- Assay variability: Different platforms show some inter-lab variability
- BBB permeability: Blood levels affected by blood-brain barrier integrity
- Age effects: Baseline GFAP increases with age